News By Tag
News By Place
Follow on Google News
Graham Company & Regenexx Announce Innovative Partnership to Reduce Orthopedic Surgical Spend for E
Partnership will allow Graham Company's clients with self-funded health plans to access Regenexx's non-surgical orthopedic alternatives as an employee benefits enhancement
According to data from Regenexx, its procedures have effectively intervened on 70% of elective orthopedic injuries and conditions where surgery was previously the only solution.* Regenexx offers a unique approach to treating orthopedic injuries non-surgically through stem cell therapy and other regenerative medicine. Procedures performed by Regenexx's specially trained physician network involve injections of custom orthobiologics, derived from the patient's own cells and natural healing agents, to treat approximately 40 orthopedic conditions. This interventional approach enables employers to save up to 70% of orthopedic costs by reducing the number of unnecessary surgeries performed annually.
"At Graham Company, we are committed to identifying solutions to help our clients control escalating health care costs while also enhancing their benefits offerings for employees," said Debra Montella, Graham Company's Vice President of the Employee Benefits Division. "Through this partnership with Regenexx, we are now able to present our self-insured clients with a unique approach that is transforming orthopedic care and driving down costs associated with surgical procedures."
This partnership also benefits the employees of clients with self-funded plans, providing them with alternative non-surgical treatment options to address orthopedic injuries or conditions. Regenexx company data found that when employees are given the choice between an invasive orthopedic surgery or its non-invasive procedure to treat orthopedic conditions, employees chose Regenexx's procedure a majority of the time. Compared to traditional orthopedic surgeries, Regenexx procedures require less downtime for patients and are considered less costly, less invasive and less risky.
"Regenexx is looking forward to expanding our mission of producing the best possible patient outcomes for Graham Company and their clients through our innovative alternative to orthopedic surgery," said Regenexx CEO Jason Hellickson. "Our patented regenerative approach to treating common orthopedic conditions is transforming the care pathway of an orthopedic patient who can now avoid a surgical encounter with less risk and less downtime."
*This data applies only to elective orthopedic surgery without fracture-related care and acute care trauma.